Clinical Trial

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

Name: Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension — clinical trial record (NCT06987097)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALEPH

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.

Trial Details

NCT Number	NCT06987097
Lead Sponsor	Nanjing First Hospital, Nanjing Medical University
Conditions	Pulmonary Arterial Hypertension (PAH)
Enrollment	410 participants
Start Date	2025-05-15
Primary Completion	2028-02-28 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-23